Investigating how Sigma1 modulators affect prostate cancer metabolism
Multifunctional Regulation of Prostate Cancer Metabolism by Sigma1 Modulators
This study is looking at how certain new medications can help treat advanced prostate cancer, especially when it stops responding to regular treatments, by targeting a specific protein that helps cancer cells grow.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10828305 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of Sigma1 modulators in the metabolism of prostate cancer, particularly in cases where the cancer becomes resistant to standard treatments. The approach involves developing small molecule inhibitors that target the Sigma1 protein, which is crucial for cancer cell growth and metabolism. By examining how these modulators interact with various signaling pathways, the research aims to identify new therapeutic strategies that could improve treatment outcomes for patients with advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those who have developed resistance to current therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone androgen deprivation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with castration-resistant prostate cancer, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Kim, Felix Jinhyun — Thomas Jefferson University
- Study coordinator: Kim, Felix Jinhyun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.